Evidence map›Paper›PMID 41092345›Full record

ArticleHuman molecular genetics2025

Genetic dissection of Huntington's disease modification by variation at RRM2B.

Kiuk Lee, Baehyun Shin, Mingyu Kim, Seong Won Lee, Young Mi Oh, Kyung-Hee Kim, Andrew Jiang, Kwanyoung Ko, Tammy Gillis, Diane Lucente and 8 more

Abstract read
In one paragraph

Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kiuk LeeMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Baehyun ShinMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Mingyu KimMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Seong Won LeeDepartment of Biomedical Sciences, Mercer University School of Medicine, 1633 1st Avenue, Columbus, GA 31901, United States.
Young Mi OhDepartment of Biomedical Sciences, Mercer University School of Medicine, 1633 1st Avenue, Columbus, GA 31901, United States.
Kyung-Hee KimMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Andrew JiangMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Kwanyoung KoMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Tammy GillisMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Diane LucenteMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Ramee LeeCHDI Management/CHDI Foundation Inc., 155 Village Boulevard, Princeton, NJ 08540, United States.
Seung KwakCHDI Management/CHDI Foundation Inc., 155 Village Boulevard, Princeton, NJ 08540, United States.
Jong-Min LeeMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Vanessa C WheelerMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Andrew S YooDepartment of Developmental Biology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, United States.
James F GusellaMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Marcy E MacDonaldMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.
Ihn Sik SeongMolecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, United States.ORCID 0000-0003-4246-3356

Funding

Dissecting the role of DNA Ligase 1 in Huntington's diseaseR01NS127866 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Ihn Sik Seong, VANESSA C WHEELER · 2023 to 2026
$2.6M
An Alternative Isoform of RRM2B as a Genetic Modifier in Huntington's DiseaseR01NS114065 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SEONG, IHN SIK · 2020 to 2024
$2.0M
CHDI Foundation Inc.National Institutes of Health National Institute of Neurological Disorders and Stroke NS091161National Institutes of Health National Institute of Neurological Disorders and Stroke NS105709National Institutes of Health National Institute of Neurological Disorders and Stroke NS107488National Institutes of Health National Institute of Neurological Disorders and Stroke NS119471NINDS NIH HHS R01 NS114065NINDS NIH HHS R01 NS127866
6 · The paper itself

Abstract

Huntington's disease (HD) is driven by somatic expansion of the HTT CAG repeat, with onset modified by genetic factors. One such modifier, 8AM1, maps to chromosome 8 near RRM2B, a gene not directly involved in the machinery that lengthens the repeat. To investigate this locus, we performed capture sequencing and identified variants at both the 5' and 3' ends of RRM2B with expected minor allele frequencies. A polymorphic frameshift variant (rs1037699) in an alternate exon 1 disrupts expression of a previously uncharacterized RRM2B isoform 2, but not isoform 1. Functional analyses in RRM2B knock-out cells and 8AM1 heterozygous LCLs suggest that isoform 2 may function at mitochondria. Several 3' variants, including a 21 bp 3'UTR deletion (rs200678743) and peak tag-SNV (rs79136984), act as cis expression quantitative trait loci. Analysis of HD onset data (n = 12,982) revealed that 5' and 3' variants contribute independently to the 8AM1 modifier effect, with full impact observed only in the absence of the frameshift variant. Knockdown of both isoforms increased neurodegeneration in HD neurons derived from pre-symptomatic patient fibroblasts, supporting an intersection of RRM2B biology and HD pathogenesis. We conclude that the 8AM1 haplotype, present in ~ 14% of Europeans, modifies RRM2B expression in a cell- and context-dependent manner, thereby accelerating HD onset in mutation carriers.

Indexed as

Huntington DiseaseRibonucleoside Diphosphate ReductaseCell Cycle ProteinsFrameshift MutationGene FrequencyGenetic Predisposition to DiseaseHumansHuntingtin ProteinNeuronsPolymorphism, Single NucleotideProtein IsoformsQuantitative Trait LociRibonucleotide ReductasesTrinucleotide Repeat ExpansionCell Cycle ProteinsHTT protein, humanHuntingtin ProteinProtein IsoformsRibonucleoside Diphosphate ReductaseRibonucleotide ReductasesRRM2B protein, humanExpression quantitative trait lociGenetic Modifiermitochondrial DNA maintenanceNeurodegenerationribonucleotide reductase

Identifiers

PMID41092345
PMCPMC13220083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.